About the Journal
About this Journal: Who We Are, and What We Stand For
Genetics and Clinical Genomics is driven by an altruistic mission: to advance global health through the transformative power of genomics. We share this vision with clinicians, researchers, educators, policymakers, patients, and the public, united in the belief that genetics and genomics can unlock solutions to some of the world's most pressing health challenges.
This mission defines us beyond the format of our content. Whether through research publications, educational initiatives, webinars, podcasts, or digital resources, Genetics and Clinical Genomics strives to remain a beacon for progress in clinical genetics and genomics.
Our priorities are rooted in:
- Advancing the creation and dissemination of genomic research to improve human health.
- Fostering equitable access to genomic knowledge and technologies.
- Promoting interdisciplinary clinical education to empower practitioners and researchers.
- Advocating for patient-centered approaches in genetic care and innovation.
- Addressing social and ethical dimensions of genomics to ensure fairness, inclusivity, and sustainability.
In pursuing these goals, we are committed to transparency, accountability, and genuine collaboration with patients, families, and communities. By amplifying underrepresented voices and prioritizing the needs of those most vulnerable, we seek to ensure the benefits of genomic progress are shared universally.
Genetics and Clinical Genomics is more than a journal; it is a partner, educator, advocate, and innovator. Whether as a trusted academic resource, an inspiring collaborator, or a call to action—we invite you to join us in this shared mission. Together, we can leverage the potential of genomics to create a healthier, more equitable world for all.
The Journal is open and publishes original unpublished articles, review topics, clinical case reports, relevant short communications, letters to the editor, as well as related opinions expressed in editorials. Manuscripts will be accepted for publication only if they have not been previously published.
The journal has started with two publication options, free and open access. The free option allows any author to submit their manuscript at no additional cost. The open access version uses the CCBY 4.0 license, which allows placement of your manuscript in HTML version and free redistribution of the manuscript.
About the Editorial
The journal is onwed by the Editorial Infomedic International, localted in:
Paitilla Medical Offices, #430
Panama, Rep. of Panama
www.infomedicint.com
First edition: June 2023.
eISSN: 2953-3139 (Spanish)
eISSN: 3072-9610 (English)
This publication is distributed under the Creative Common licenses.
For more information contact the publisher.
The Journal assumes no responsibility for the consequences of the use of the information contained in its publications. They reflect the exclusive point of view of their authors.
Peer Review Process
The Genetics and Clinical Genomics Journal uses a double-blind peer review system, in which both reviewers and authors remain anonymous throughout the review process. Each manuscript is evaluated by at least two independent expert reviewers. The Editor-in-Chief, with the advice of the Associate Editors, makes the final decision on acceptance, revision, or rejection, based on the reviewers’ recommendations and the journal’s editorial standards.
Governing Body
The Genetics and Clinical Genomics Journal is guided by a distinguished Editorial Board composed of field-leading professionals. Their full names and affiliations are also publicly listed on the journal’s website under the "Editorial Team" section, demonstrating transparency and scholarly governance. Current members include:
Editors
Dr. Jorge D. Méndez, MD, MS, PhD – Editor-in-Chief, Prenatal Diagnosis by CGH, Laboratory of Molecular Diagnostics, CHUL, Canada
Dr. Bary Bigay, MD – Precision Oncology and Molecular Genetics, Dominican Republic
Dr. Enrique D. Austin, MD – Cancer and Tumoral Genetic Diseases, Clinical Researcher, INDICASAT, Panama
Dr. Lorena Salazar García, PhD – WGS Sequencing, Panels and pPCR Consultant, Spain
Dr. Lina Johanna Moreno Giraldo, MD – Pediatrics, Epigenetics and Network Interactions, Libre Cali University, Colombia
Dra. Katlin de la Rosa Poueriet, MD – Pediatrics, Molecular Diagnostics by NGS, ChromoMED Institute, Dominican Republic
Associate Editors
Dr. Tania Herrera Rodríguez, MD – Maternal-Fetal Medicine, Hospital Punta Pacífica Área Materno Fetal, Panama
Dra. Indira Herrera, MD – Pediatrics, Genetics and Genomic Service, Children’s Hospital, Panama
Dr. Luis Leonardo Flores-Lagunes, MD – Molecular Diagnosis by NGS, Genomic Medicine Institute, Mexico City, Mexico
Dr. Luis Gustavo Celis, MD – Mutations, Malformations, and Chronic Degenerative Disorders, La Sabana University, Colombia
Dr. Karen Courville, MD – Nephrology, Dr. Gustavo N. Collado Hospital, Panama
Dr. Stanley Wu, MD – Oncology-related specialization, National Oncology Institute, Panama
Dr. Johan Serrano, MD – Internal Medicine, Panama
Dra. Carolina Rivera Nieto – Clinical Genetics, Colombia
Dr. Ricardo Fernández-Ramires – Genetic Counseling, Hereditary Cancer, Chile
Dr. Moisés Cukier, MD – Oncologic Surgery, Panama
Dr. Ignacio Véliz, MD – Oncology, Personalized Oncologic Treatment, Panama
Dra. Celia Cantón, MD – Clinical Genetics, Dysautonomia, and Muscular Dystrophies, Panama
Dr. Horacio Lucero – Regional Medicine Institute, UNNE, Argentina
(Note: This list reflects the Editorial Board as of Sept. 7th, 2025. For the most up-to-date list, please visit the [Editorial Team page] on our website.)
Publishing Schedule
The Genetics and Clinical Genomics Journal publishes three issues per year (April, August, and December). Articles are released as part of these scheduled issues to ensure timely dissemination of research.
Access Policy
The Genetics and Clinical Genomics Journal is a fully open access journal. All articles are freely available online immediately upon publication, with no subscription fees or pay-per-view charges. Readers are permitted to read, download, copy, distribute, print, search, or link to the full texts of articles without restriction, in accordance with the selected Creative Commons license chosen by the author.
Archiving and Digital Preservation
The Genetics and Clinical Genomics Journal ensures the long-term preservation and accessibility of its published content through inclusion in Portico and through deposit in the Biblioteca Nacional de Panamá for permanent preservation. These archiving arrangements guarantee that all articles remain permanently available to the scholarly community, even in the event the journal ceases publication.
Revenue Sources
The Genetics and Clinical Genomics Journal may be financed through a variety of sources, including Article Processing Charges (APCs), institutional support, advertising, sponsorships, reprints, and organizational funding. Regardless of the source, all editorial decisions are made independently, based solely on academic merit and relevance, and are never influenced by financial considerations.
Advertising Policy
The Genetics and Clinical Genomics Journal may include advertising content in its online and print platforms in the future. All advertisements will be clearly distinguished from editorial content and will have no influence on editorial decisions. The types of advertising accepted will be consistent with the journal’s mission and ethical standards. Decisions regarding advertising placement are made by the publisher and are kept completely separate from the editorial and peer review process. No misleading medical products, no ads linked to the editorial board are allowed.
Direct Marketing Policy
The Genetics and Clinical Genomics Journal may occasionally engage in direct marketing activities, such as sending targeted calls for papers or announcements to researchers in relevant fields. All such activities are conducted in a professional, appropriate, and transparent manner, and never include misleading information. Marketing activities are designed solely to promote legitimate scholarly communication and participation in the journal. No Spam or unsolicited marketing practices are implemented or allowed.
Best Practices
The Journal adheres to the best practices, recommendations and procedures proposed by the Committee on Advertising Ethics (COPE) for the publication of scientific journals.
Authors must take into account the principles of the World Medical Association on human research and the well-known Declaration of Helsinki (https://www.wma.net/policies-post/wma-declaration-of-helsinki- principios-éticos-para-la-investigación-medica-en-sujetos-humanos/).
The Journal also endorses the ICMJE recommendations for the conduct, writing, editing and publication of papers in medical journals (http://www.icmje.org/recomendaciones/).
Clinical studies should use CONSORT or TREND guidelines when appropriate. Meta-analysis studies should follow PRISMA guidelines. Diagnostic reports should follow STARD guidelines. Epidemiological studies should consult with the STROBE Initiative. Microarray reports should follow MIAME guidelines and be published in accessible repositories. In biomedical research, authors can evaluate BioShari guidelines.
Human studies
In the case of clinical experiments in humans, the studies must have institutional and ethics committee approval, statements of the implementation of good clinical practices, and document how informed consent was obtained. If requested by the Journal, authors should provide this material. This includes following the principles of the Declaration of Helsinki. In addition, registration of clinical trials with WHO or ICMJE may be requested.
Animal studies
Animal studies must be conducted in accordance with internationally accepted standards. Institutions must obtain approvals from their institutional or equivalent committees (ethics committees). This information should be reported in the manuscript.
Informed Consent
Studies should follow privacy standards and request signed informed consent. The Journal requires the request of consent by the investigators to the subjects of the study, under the WHO/WHO international regulations and compliance with local regulations. Studies containing personally identifiable information will not be accepted.
Declaration of conflict of interest and sources of funding
Authors should also declare any possible conflict of interest in a short paragraph at the end of their manuscript. Our journal is regulated under the guidelines of the International Committee of Medica Journal Editors (ICMJE). This declaration includes owning stock, providing consulting services, organizational memberships, financial partnerships, travel fees, or royalties. A conflict of interest should be identified by any direct or indirect benefit, whether financial or not, derived from the publication and provided by a third party. Likewise, authors should disclose the source of funding for their work or any sponsor that supported the research directly or indirectly.
When the author submits the manuscript, each listed co-author will receive an e-mail with a link to a digital potential conflict of interest form. This form should be filled out by each co-author by clicking on the submit button. The model form was taken from the International Committee of Medical Editors.
Image of the Digital Conflict of Interest form/Image of the Digital Conflict of Interest form
Once the material is received you will be sent an email informing you of this. Your paper will be read by the editors, and if it is accepted for review you will receive a notification. It will be subject to peer review. It will then be forwarded to you with the editors' comments, questions and suggestions. They should return the responses and changes in a separate file, where the changes are shown and marked. When publications are accepted, authors should take into account that this material cannot be published in another journal. The journal reserves the right to require compliance with these rules.
Policy on the Use of Generative AI
The Genetics and Clinical Genomics Journal acknowledges the use of Generative Artificial Intelligence (GenAI) tools in academic publishing. GenAI cannot be credited as an author. Authors may use these tools for language editing or formatting support, but remain fully responsible for the accuracy, originality, and validity of the content. All uses of GenAI must be disclosed in the acknowledgments (e.g., tool and scope). GenAI must not be used to generate data, results, references, or peer reviews. Editors and reviewers may use AI for minor language assistance, but editorial and peer review judgments must be human-made.
Cost of publication
License and Copyright Policy
Genetics and Clinical Genomics Journal is committed to providing authors with flexible open access publishing options that maximize both visibility and compliance with international standards. All articles are published under a Creative Commons license chosen by the author at the time of acceptance. Authors retain copyright while granting the journal an exclusive license to commercialize, publish and distribute the article. To accommodate funder mandates (e.g., NIH, Plan S, Horizon Europe) and to support equitable access to publishing opportunities worldwide, we offer a choice of licenses and article processing charges (APCs) that vary depending on license type and the author’s country income classification (based on World Bank categories). Our recommended license is CC BY, as it ensures the broadest dissemination, indexing compatibility, and compliance with global open access policies.
The first method is to publish through the Open Access (CC-BY, CC-BY-NC) options depending on the license you choose at the moment of submission. The processing fees are only charged once the is accepted for publication by the journal. Any work that has been financed must be submitted through one of the Open Access option. Cosult with your granting institution to determine the best license for your work.
At the moment, we offer fee waiver for students, residents and non-funded work. This License allows anyone to submit their manuscript, and if the manuscript is accepted, it will be published at no cost. This agreement also grants the Editorial an exclusive license and rights to publish and distribution under the license CC BY-NC-ND. This is specially beneficial for Students, Residents, or groups that are not funded.
Processing fees table
| License Option | High-Income Country Authors | Low-/Middle-Income Country Authors* | |
|---|---|---|---|
| CC BY | $850 USD | $450 USD | |
| CC BY-NC | $650 USD | $250 USD | |
| CC BY-NC-ND (for students, residents and unfunded research) | Fees waived | Fees waived | |
Distribution, use and license
Through these licenses, the authors grant exclusive license to the Publisher for the reproduction and distribution of the material. The published content may be used for individual and academic use, and not for commercial use or redistribution. For commercial use of the material, or its distribution, redistribution requires written permission from the Publisher. This may vary depending on the license choosen by the author.
Authors’ rights and open access options
The Journal Licence allows authors to use their articles for their own non-commercial purposes without seeking permission from us – the only condition being that a full reference or link to the original is included.
Publication Ethics and Publication Malpractice Statement
The Genetics and Clinical Genomics Journal is committed to upholding the highest standards of ethical publishing. We follow the guidelines of the Committee on Publication Ethics (COPE) to ensure integrity, transparency, and accountability in all aspects of the editorial process.
Authors’ Responsibilities
Authors must submit original work, free of plagiarism, fabrication, or falsification of data. All sources must be properly cited and acknowledged. Conflicts of interest must be disclosed. Authorship is limited to individuals who have made a significant intellectual contribution to the work.
Editorial Responsibilities
Editors must ensure fair, unbiased, and timely review of all submissions. Editorial decisions are based solely on academic merit and relevance to the journal’s scope. Editors must maintain confidentiality and avoid conflicts of interest.
Reviewers’ Responsibilities
Reviewers are expected to provide objective, constructive, and timely evaluations. They must treat all manuscripts as confidential documents, refrain from using unpublished material for personal advantage, and declare any conflicts of interest.
Publisher and Journal Responsibilities
The journal is committed to maintaining the integrity of the academic record. Cases of suspected misconduct (plagiarism, duplicate publication, authorship disputes, data manipulation) will be investigated following COPE recommendations. When necessary, the journal will publish corrections, retractions, or expressions of concern.
Malpractice Policy
Any form of unethical publishing behavior is unacceptable. Allegations of misconduct will be taken seriously, investigated promptly, and addressed with appropriate actions to protect the integrity of the scientific record.
Errata
The journal publishes corrections, errata, and retractions when necessary, to maintain the accuracy of the scientific record
Complains
Authors, reviewers, or readers may submit complaints or appeals to the editorial office by email. All cases will be handled fairly, confidentially, and in accordance with COPE guidelines
Version September 2025
